Three numbers, taken together, describe where the hearing loss field stands better than any single announcement. There are more than 3,200 gene, cell, and RNA therapy trials running worldwide as of the third quarter of 2025, per the ASGCT and Citeline landscape report. Adeno-associated virus gene therapy trials, the delivery platform most inner-ear programs ride on, numbered 343 by industry tallies, up by a third in a year, according to PackGene's half-year AAV analysis. And venture investors put $9.1 billion into biotech in the first half of 2026, the strongest first half since 2022.
Add the strategic money to the statistical money. Eli Lilly bought Adverum Biotechnologies in October 2025 and took global rights to MeiraGTx's LCA4 retinal gene therapy in November, two deals that assembled an ophthalmology gene therapy franchise in a single quarter, and the same company has carried an inner-ear gene therapy program since acquiring Akouos in 2022. The hearing loss field has its infrastructure, its capital, and its validation from large pharma. What it does not yet have is a payment system for what it is about to produce.
That is the shift this article makes. Earlier coverage on this site asked how gene therapy for deafness is offered. The harder question now is how it gets paid for, because the science has moved faster than the pricing machinery, and the companies positioned to answer the pricing question are the ones that will define the standard of care.
The field's biggest door just opened in France
The most common genetic cause of congenital hearing loss is a mutation in GJB2, the gene for a protein called connexin 26. It is the largest single door into the entire field, and on August 31, 2026, France's medicines regulator, the ANSM, authorized a clinical trial of SENS-601, Sensorion's GJB2 gene therapy under its Fast Track assessment process.
The therapy is SENS-601, from Sensorion, the Montpellier-based biotech that has spent the last several years building the delivery and trial machinery this exact moment requires. HearConnex, the newly cleared Phase I/II study, runs in two parts: a safety stage testing two ascending doses delivered unilaterally into the inner ear, then an efficacy stage delivering the selected dose to both ears. The trial relies on Sensorion's proprietary intra-cochlear injection system, the device work the company first proved out in its Audiogene trial of SENS-501, its earlier otoferlin program. With authorization granted in France, Canadian trial applications are filed, with an Australian filing and a U.S. IND targeted by the end of 2026, first patient dosing expected in early 2027, and clinical data expected through 2027.
The evidence base underneath SENS-601 is small, honest, and unusually clean for this stage. The Audiogene trial's six-month update, reported in March 2026, showed six treated patients with no serious adverse events, and in the higher-dose cohort, two of three patients with hearing improvements that appeared by month three and were still present at month six. That is the pattern that matters in first-in-human inner-ear work: the surgery is reproducible, the safety holds, and the dose response points the right direction.
Sensorion has also loaded the executive bench for the commercialization problem, not just the clinical one. Fred Chereau, who took over as chief executive on June 1, 2026, spent more than three decades in rare disease drug development, most recently as senior vice president of strategy and business development at Alexion, AstraZeneca's rare disease unit, after running the gene therapy company LogicBio. A January 2026 financing of 60 million euros, including 20 million from Sanofi, funds the company's runway through the end of 2027.
What changes when the cause itself becomes the target
The strategic claim behind the whole field is that hearing loss medicine is where kidney medicine stood a decade ago: a large, common problem that drug development had largely written off, until new biology suddenly made it tractable. The analogy is fair. For decades, the standard tools for hearing loss, hearing aids and cochlear implants, addressed sound delivery rather than the underlying cause, and neither reversed the biology. Roughly a third of adults who could benefit from hearing aids actually use them, which leaves a vast treated-nothing population alongside the treated-imperfectly one.
A gene therapy aimed at the root cause changes the clinical question from amplification to restoration. The timing question is where the medicine gets interesting. Programs like Audiogene dosed children aged 6 to 31 months because early childhood is the window when the developing brain is most plastic for language acquisition, and restoring hearing inside that window is what gives a treated child the best odds of developing spoken language. That is why Sensorion's trials and its competitors' trials skew toward infants and toddlers rather than adults. Treat the cause early enough, and the argument goes, and the developing brain gets to build on a signal it would otherwise never receive.
Families will weigh that argument differently, and they are entitled to. The deaf community holds varied and deeply held views about medical intervention for hearing loss; some families pursue every available option, others do not, and no clinical program changes the validity of either position. The data will speak to the families who choose treatment, and it will do so one small cohort at a time.
The field's first approval arrived on April 23, when the FDA cleared Regeneron's Otarmeni for OTOF-related hearing loss, an ultra-rare condition affecting roughly 50 newborns a year in the United States. That approval, in a different gene than the one SENS-601 targets, proved the delivery path works. GJB2-linked hearing loss is a far larger population, and every Sensorion result so far remains an early signal, not a settled outcome.
The pricing conversation starts before the approval does
Here is the uncomfortable arithmetic the field is running toward. The one-time gene therapies approved so far have carried list prices that reset expectations: around $2.1 million for Zolgensma, $3.5 million for Hemgenix, $3.2 million for Elevidys, $4.25 million for Lenmeldy. Those prices were built for ultra-rare diseases with tiny patient populations. Hearing loss inverts the model: GJB2-linked hearing loss is far more common than the diseases those first gene therapies treated, which should push price per patient down, but the therapy is still a single intervention meant to last a lifetime, which pushes value up. Somewhere between those two forces is a number the market has not yet named.
The benchmark that will anchor the conversation already exists, and it is a device rather than a drug. Cochlear implantation, with surgery, hardware, and a lifetime of mapping and maintenance, is the economic frame payers already understand for severe hearing loss. A one-time therapy priced against that benchmark, amortized over decades of avoided device care, has a straightforward value story to tell.
What it does not yet have is a payment mechanism. The "once and done" pricing debate that gene therapy companies and payers have been circling for years, installment plans, outcomes-based annuities, rebates tied to durability, has never been settled, only postponed. Every new one-time therapy has arrived with a bespoke arrangement. The field's first approval chose a third answer: Regeneron announced it will provide Otarmeni free of charge to clinically eligible U.S. patients, apart from surgical costs, a model built for an ultra-rare population of roughly 50 newborns a year. That answer does not transfer to GJB2-sized populations, which is precisely the arithmetic the rest of the field is walking toward. The hearing loss field, with its larger populations and its device benchmark, is a natural place for a more standardized answer, and the companies that help build that answer early will shape the market they later sell into.
One policy wrinkle complicates the arithmetic for a French company specifically. Most Favoured Nation drug pricing proposals, which would benchmark U.S. prices to what other countries pay, are designed to lower American drug costs, and their advocates make that case straightforwardly. Their opponents, including much of the gene therapy industry, argue the same mechanism would break the economics of one-time therapies precisely because other wealthy countries already pay less, and the U.S. premium is what makes the multi-billion-dollar development bet rational. Both positions are live in Washington policy debates, and for a non-U.S. biotech whose biggest future market is American, the outcome will define what "once and done" is worth.
Delivery is the moat nobody photographs
The least glamorous part of the Sensorion story is the most durable. The reason direct delivery to the relevant tissue keeps appearing in every serious hearing loss program is biological: the inner ear sits behind the blood-labyrinth barrier, isolated from the bloodstream by design, which is excellent for hearing and hostile to systemically delivered drugs. Local administration means a lower dose, less systemic exposure, and a safety profile that stays local.
It also means the device matters as much as the vector. A gene therapy that requires a surgery only a handful of specialists can perform is a niche product no matter how good the biology is. A therapy delivered through a reproducible injection system, proven across surgeons and trial sites the way the Audiogene experience tested it, is a standard of care in waiting. Sensorion's injection system, refined through its first trial and now carrying its second, is the part of the pipeline that competitors cannot copy from a paper.
That is the shape of the field's winners taking form. The companies that will define hearing loss gene therapy are the ones holding three things at once: a program in the largest genetic indication, a delivery system with a surgical track record, and an early answer to the pricing question. Sensorion holds the first two demonstrably and is positioned to argue the third. The GJB2 door is open in France, the Canadian filing is under review, and a U.S. filing is targeted for the end of the year. The clinical data that begins arriving in 2027 will tell the field whether its new standard of care is real.
The question has changed, and that is what a tipping point looks like from the inside. For years the field asked whether biology could restore hearing. Otarmeni's April approval answered that question for one gene, and the trials now running suggest the answer will generalize. The question that now decides the field's winners is the one nobody built a trial for: who pays, how, and for how long the result is expected to last.
Primary sources
- ASGCT and Citeline Q3 2025 landscape report for the trial counts.
- BioPharma Dive for H1 2026 venture funding.
- Hearing Review for the ANSM authorization and HearConnex design.
- Sensorion for the company's pipeline and program timelines.
- Drug Discovery News for the Lilly-Adverum and Lilly-MeiraGTx deals.
- PackGene for the AAV trial tallies.
- Nasdaq for Fred Chereau's appointment and background.
- Regeneron press release for the Otarmeni approval, the CHORD trial results, and the free-of-charge access model.